Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease.
about
Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive ReviewReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseTiming of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendationsHealthcare maintenance in elderly patients with inflammatory bowel disease.Progressive outer retinal necrosis and immunosuppressive therapy in myasthenia gravisIncreased risk for non-melanoma skin cancer in patients with inflammatory bowel diseaseRisk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel diseaseRisk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study.Updates in vaccination: recommendations for adult inflammatory bowel disease patients.Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France.Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's DiseasePreventative Care in the Patient with Inflammatory Bowel Disease: What Is New?Increased risk of pneumonia among patients with inflammatory bowel disease.Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression.Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease.Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda.Vaccinating Patients With Inflammatory Bowel Disease.Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel diseaseIncreased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics.The challenge of pain management in patients with myasthenia gravis.Incidence of herpes zoster in patients with altered immune function.Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts.Clinical outcomes and management of inflammatory bowel disease in the older patient.Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops.Vaccinating the inflammatory bowel disease patient.Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications.The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus.Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary.The risk of herpes zoster in patients with ankylosing spondylitis: Analysis of the Korean National Health Insurance Service - Sample cohort database.Herpes Zoster Vaccine Response in Inflammatory Bowel Disease Patients on Low-dose Immunosuppression.Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease.Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study.Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.Vaccination and Health Maintenance Issues to Consider in Patients With Inflammatory Bowel Disease.Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications.
P2860
Q26748712-FE17ADE4-E020-4D14-8DB6-EE36131F1111Q26822029-7CEA67DE-E847-4E09-9D98-AEC14773762DQ33385516-6FDE0714-1A83-4362-91A8-C4A7BE5ABEF3Q33621700-883CE0C4-7727-4699-9652-6F236E924A62Q33675585-3C12F875-DFE3-4A1C-A700-DC0A3E6434A2Q33727211-C9D14C0A-F8D8-44EB-B938-9E4300489A81Q33786255-457EF963-F3A0-4535-81D3-D115DAE72B44Q34693477-E7517D2C-3843-4CB9-A26A-363E3708BC18Q35188575-31DB261B-1F1C-42A7-BDA0-076804D2A507Q35749707-97D32B81-E861-450A-AB22-F5379FDB5B2CQ35763489-AC61992A-5B17-46FE-B378-354F1F7E91A7Q35984547-F8565C7C-9E7F-48F7-99B3-18B83AA663ACQ36219145-27CCBDFA-62C6-4A75-B9D9-44524700BD12Q36496958-E1D2B94D-4C77-4388-B93E-A5F5F7A2204FQ36897967-180BC29F-0CC7-43B8-9983-C696493B2FE2Q36932760-140A9F70-977D-4356-98D0-4EAE227A5315Q37087227-0B5D739F-6600-4137-9285-C9397A3B2DB8Q37421543-82F95C6E-C608-47E1-B1B7-C03F3E00D446Q37429242-BCB1B10A-B09D-4429-9667-7B1267AE2B08Q37456737-79E1F8BC-40E3-414F-9F2A-E12CC629697DQ37484842-2FE78829-BD99-4E69-923F-7930E8A48573Q37492480-E41D7AFA-2B9A-450A-90C0-2D705EFC6A4EQ37577775-B05201CA-0F6C-41DD-9705-B63C32502C6DQ37670193-F99B356D-F29E-4566-A1E3-CFA7599A9BEDQ37781314-68EC2F92-695C-4DC6-995C-693278AF7BB2Q38073185-1C68AA46-E025-466F-ABC4-18483790E2F2Q38179468-D78D6981-E4DA-40C0-B9FE-41EB6EAF511DQ38197891-8694D373-6AD7-41F9-89F3-287A92D9B36AQ38243693-F1FAC3AD-EADC-4B19-B921-9F59D522F115Q38626287-3FEF3EFA-189A-48E7-9BA2-9B157BCA4DFBQ38682515-EBF1B57A-BA65-4752-8B71-0DABBCE32E34Q38947199-000F5CF3-7A2B-4042-8694-DA13B54D1A1CQ40184103-19D4031A-BEE8-48EA-928C-7AAAFDB3E627Q40723475-168F5FCA-AB17-4B84-96B3-A591C1D05B59Q41222715-EB40D18F-B349-41BF-8407-CA7DFBC56DCCQ41680666-C917BF9C-D56A-4806-8258-A91FBD664671Q45093232-70F53028-2AB3-4843-B9BE-FDBCE429DAE9Q45966647-EBA51541-6483-4C1E-94EE-AD3FFD7B9706Q47555158-A8BCC596-CC45-4216-80AB-F6A36381F824Q48288845-A4B5D1BE-DA4F-434A-97B3-30E423F79A7C
P2860
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Incidence and risk factors for ...... th inflammatory bowel disease.
@en
type
label
Incidence and risk factors for ...... th inflammatory bowel disease.
@en
prefLabel
Incidence and risk factors for ...... th inflammatory bowel disease.
@en
P2093
P1476
Incidence and risk factors for ...... th inflammatory bowel disease.
@en
P2093
Ebbing Lautenbach
Gauree Gupta
James D Lewis
P304
P356
10.1016/J.CGH.2006.09.019
P407
P577
2006-12-01T00:00:00Z